Drug Trial Radar · NCT07202897
LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
532
Planned (sponsor's estimate)
Start
Jan 7, 2026
Primary completion
Jan 7, 2032
Study completion Jan 7, 2033
Sponsor
- Lead sponsor
- Rennes University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hypertrophic cardiomyopathy (HCM) is a common (\> 1/500 in the general adult population) genetically transmitted disease impacting markedly patients' lives from the early ages to the latest. The phenotype as the prognosis of HCM may greatly differ from one patient to another: most patients present no or few symptoms and a near-normal lifespan, while others are severely symptomatic. Paroxysmal, persistent or permanent atrial fibrillation (AF) is frequent in HCM, occurring in more than 20%-25% of patients and is often considered as an important turning point for the quality of life of these patients. AF decreases cardiac output and exercise tolerance, increases hospitalization rate, and markedly increase the risk of embolic stroke with the need for life-anticoagulation. It has been shown that stroke may precede AF discovery and that it may occur at young ages with devastation consequences. AF also may trigger sudden cardiac death. Observational studies have been conducted to search for parameters which correlate with the risk of AF (P wave duration and supra-ventricular burst on the Holter-ECG monitoring, L-wave morphology, degree of hypertrophy, clinical parameters-comorbidities, and size of the left atrium) with no real impact on clinical management. Left Atrial strain (LA-strain) has been recently demonstrated relevant (for instance our pilot work (for predicting stroke and/or AF (a cut-off of 15% is highly specific, 20% being the optimal cut-off). LA-strain (cut-off 20%) could be used for defining the patients that might require preventive anticoagulation therapy. A randomized clinical trial is needed to extend the use of anticoagulation therapy to patients in sinus rhythm but identified to be at risk for AF. Of note, it has been demonstrated that in this population, stroke occurred in 67% of the patients without any clinical atrial arrhythmia.
Conditions
- Hypertrophic Cardiomyopathy (HCM)
Interventions
Anticoagulant treatment RivaroxabanDrug
Anticoagulant treatment Rivaroxaban in addition to best medical therapy
Best medical therapyOther
Best medical therapy alone
Primary outcomes
What the sponsor says the trial is designed to measure.
- all-cause death, myocardial infarction, stroke and systemic embolismTime frame: 2 years
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
CHU Angers
Angers, France · Not yet recruiting
CHU Bordeaux Haut-Levêque
Bordeaux, France · Not yet recruiting
CHU Brest - Hôpital La Cavale Blanche
Brest, France · Not yet recruiting
CHU Caen
Caen, France · Not yet recruiting
CHU Dijon - Hôpital François Mitterrand
Dijon, France · Recruiting
CHU Grenoble Alpes
Grenoble, France · Not yet recruiting
CHU Lille
Lille, France · Not yet recruiting
APHM - Hôpital La Timone
Marseille, France · Not yet recruiting
CHU de Nantes -Hôpital Nord Laennec
Nantes, France · Not yet recruiting
AP-HP Höpital la Pitié-Salpétrière
Paris, France · Not yet recruiting
APHP Hopital Européen Georges Pompidou
Paris, France · Not yet recruiting
APHP, Hôpital Lariboisière
Paris, France · Not yet recruiting
CHU Rennes - Hôpital Pontchaillou
Rennes, France · Recruiting
CHU de Rouen
Rouen, France · Not yet recruiting
CHU Rangueil Toulouse
Toulouse, France · Not yet recruiting
CHU de TOURS - HOPITAL TROUSSEAU
Tours, France · Not yet recruiting
CHU Nancy
Vandœuvre-lès-Nancy, France · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.